[Skip to content]

European Parkinson's Disease Association
Search our Site

Research papers


Measurement and diagnosis research papers

  • JNNP Volume 84 Chronological changes of 123I-MIBG myocardial scintigraphy and clinical features of Parkinson's diseaseConclusions Follow-up studies of MIBG divided the patients with PD into two major subgroups. A subgroup of patients with PD with normal or mildly low MIBG uptakes at the early stages of illness was characterised by female-dominant, young onset, slow progression in motor dysfunctions and preserved cognitive function. 02 May 2015
  • Parkinsonism & Related Disorders Volume 21 Issue 5 Biomarkers of cognitive decline in Parkinson's diseaseGiven that the underlying mechanisms of cognitive decline or dementia associated with PD remain unclear, there is currently no mechanism-based treatment available. Identification of biological markers, including neuroimaging, biofluids and common genetic variants, that account for the heterogeneity of PD related cognitive decline could provide important insights into the pathological processes that underlie cognitive impairment in PD. 01 May 2015
  • Movement Disorders Volume 30 Issue 5 International validation of a behavioral scale in Parkinson's disease without dementiaThe Ardouin Scale of Behavior in Parkinson's Disease is a new instrument specifically designed for assessing mood and behavior with a view to quantifying changes related to Parkinson's disease, to dopaminergic medication, and to non-motor fluctuations. This study was aimed at analyzing the psychometric attributes of this scale in patients with Parkinson's disease without dementia. 15 April 2015
  • Movement Disorders Volume 30 Issue 4 A population-based study on combined markers for early Parkinson's diseaseWhen combining SN+ and hyposmia, PPV increased to 17.6%, with a sensitivity of 51% and a specificity of 98%. Both SN+ and hyposmia offer good enrichment towards PD and ppPD, are stable against other diseases, and the combination of markers highly increases specificity. However, if the combination of SN+ and hyposmia were used as criterion for PD diagnosis, almost half of clinically definite PD and more than 90% of ppPD would have been missed. 15 April 2015
  • xxx Speech disorders reflect differing pathophysiology in Parkinson's, progressive supranuclear palsy and multiple system atrophyObjective speech measurements were able to discriminate between APS and PD with 95 % accuracy and between PSP and MSA with 75 % accuracy. Dysarthria severity in APS was related to overall disease severity (r = 0.54, p = 0.006). Dysarthria with various combinations of hypokinetic, spastic and ataxic components reflects differing pathophysiology in PD, PSP and MSA. Thus, motor speech examination may provide useful information in the evaluation of these diseases with similar manifestations. 01 April 2015
  • Test tube In vivo gastric detection of α-synuclein inclusions in Parkinson's diseaseNeuropathological diagnosis based on α-synuclein immunostaining showed a sensitivity of 85% (95% confidence interval [CI] 62.1-96.8), specificity of 95% (95% CI 76.2-99.9) and area under the receiver operating characteristics curve (AUC) of 0.90 (95% CI 0.80-1.00). 01 April 2015
  • JNNP Volume 84 Frequency and profile of Parkinson's disease prodromi in patients with malignant melanomaConclusions History of melanoma was associated with increased prevalence of prodromal markers of PD. Their predictive value needs to be established in long-term investigations. The similarity of serum iron characteristics found in patients with melanoma and PD deserves further research. 28 March 2015
  • Parkinson's Disease Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System AtrophyStudy findings suggest that an assessment of IENFD in biopsied skin could be a useful means of differentiating between PD and MSA but that detection of α-synuclein aggregates on cutaneous nerves in the distal sites of the body is insufficiently sensitive. 24 March 2015
  • JNNP Volume 84 Identification of novel biomarkers for Parkinson's disease by metabolomic technologiesConclusions: Metabolomic analysis detected biomarkers associated with PD pathogenesis and disease progression. Since critical metabolic biomarkers need to be identified in PD, future studies should include assay validation and replication in independent cohorts. 20 March 2015
  • Movement Disorders Volume 29 Issue 6 Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's diseaseThis study suggests the existence of a subgroup of patients who show urinary symptoms along with an overall higher motor and nonmotor burden. Such patients are prone to manifest a rapid functional decline over the first 4 years of the disease. Urinary symptoms might be a clinical marker of severity as well as a possible nonmotor subtype of PD. 15 March 2015
Page: [10-] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [+21]